Aleš Pleskovič1, Marija Šantl Letonja2, Andreja Cokan Vujkovac3, Jovana Nikolajević Starčević4,5, Martin Caprnda6, Eduard Curilla7, Ioana Mozos8, Peter Kruzliak9,10, Robert Prosecky11, Daniel Petrovič5,12. 1. 1 Department of Cardiology, University Medical Centre, University of Ljubljana, Ljubljana, Slovenia. 2. 2 General Hospital Rakičan, Murska Sobota, Slovenia. 3. 3 General Hospital Slovenj Gradec, Slovenj Gradec, Slovenia. 4. 4 Division of Internal Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia. 5. 5 Institute of Histology and Embryology, Faculty of Medicine, University in Ljubljana, Ljubljana, Slovenia. 6. 6 2nd Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia. 7. 7 Department of Cardiology, East Slovak Institute of Cardiovascular Diseases, Kosice, Slovakia. 8. 8 Department of Functional Sciences, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania. 9. 9 Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic. 10. 10 Research and Development Services, Brno, Czech Republic. 11. 11 Department of Internal Medicine, Brothers of Mercy Hospital, Brno, Czech Republic. 12. 12 International Center for Cardiovascular Diseases MC Medicor, Izola-Ljubljana, Slovenia.
Abstract
BACKGROUND: The study was designed to test the possible association between either polymorphisms of the matrix metalloproteinase-9 (MMP-9) gene (rs17576, rs3918242) or the MMP-3 5A/6A gene polymorphism (rs3025058) with markers of carotid atherosclerosis in patients with type 2 diabetes mellitus (T2DM). The second aim of the study was to demonstrate an association between either the rs17576, rs3918242 or rs3025058 and subclinical markers of coronary artery disease in the same subset of patients with T2DM. PATIENTS AND METHODS: A total of 595 subjects with T2DM and 200 subjects without T2DM (control group) were enrolled in the prospective study. Subclinical markers of carotid atherosclerosis were assessed ultrasonographically. Additionally, in a subset of subjects with T2DM a coronary computed tomography angiography (CCTA) was performed for diagnostic purposes. Genotyping of all three polymorphisms (rs17576, rs3918242, rs3025058) was performed with real-time PCR systems. RESULTS: The comparison of atherosclerosis parameters was performed with regard to different genotypes of MMP-9 rs17576, rs3918242, and MMP-3 rs3025058 polymorphisms upon enrolment and during follow-up. In our study, we found an association between the MMP-3 rs3025058 and CIMT at the time of recruitment. Multiple linear regression analysis revealed the association of either the A- allele or the A- genotypes of the rs3025058 (MMP-3) with carotid intima media thickness (CIMT) progression in a 3.8-year follow-up. We demonstrated the effect of the rs3025058 on subclinical markers of coronary atherosclerosis (coronary calcium score, number of coronary arteries with more than 50 % stenosis, and presence of at least one vessel with more than 50 % stenosis). CONCLUSIONS: We found an association between the MMP-3 rs3025058 and subclinical markers of carotid (CIMT) and coronary atherosclerosis at the time of recruitment. Moreover, we demonstrated the effect of the MMP-3 rs3025058 on CIMT progression in the 3.8-year follow-up in patients with T2DM.
BACKGROUND: The study was designed to test the possible association between either polymorphisms of the matrix metalloproteinase-9 (MMP-9) gene (rs17576, rs3918242) or the MMP-3 5A/6A gene polymorphism (rs3025058) with markers of carotid atherosclerosis in patients with type 2 diabetes mellitus (T2DM). The second aim of the study was to demonstrate an association between either the rs17576, rs3918242 or rs3025058 and subclinical markers of coronary artery disease in the same subset of patients with T2DM. PATIENTS AND METHODS: A total of 595 subjects with T2DM and 200 subjects without T2DM (control group) were enrolled in the prospective study. Subclinical markers of carotid atherosclerosis were assessed ultrasonographically. Additionally, in a subset of subjects with T2DM a coronary computed tomography angiography (CCTA) was performed for diagnostic purposes. Genotyping of all three polymorphisms (rs17576, rs3918242, rs3025058) was performed with real-time PCR systems. RESULTS: The comparison of atherosclerosis parameters was performed with regard to different genotypes of MMP-9rs17576, rs3918242, and MMP-3rs3025058 polymorphisms upon enrolment and during follow-up. In our study, we found an association between the MMP-3rs3025058 and CIMT at the time of recruitment. Multiple linear regression analysis revealed the association of either the A- allele or the A- genotypes of the rs3025058 (MMP-3) with carotid intima media thickness (CIMT) progression in a 3.8-year follow-up. We demonstrated the effect of the rs3025058 on subclinical markers of coronary atherosclerosis (coronary calcium score, number of coronary arteries with more than 50 % stenosis, and presence of at least one vessel with more than 50 % stenosis). CONCLUSIONS: We found an association between the MMP-3rs3025058 and subclinical markers of carotid (CIMT) and coronary atherosclerosis at the time of recruitment. Moreover, we demonstrated the effect of the MMP-3rs3025058 on CIMT progression in the 3.8-year follow-up in patients with T2DM.
Authors: Ioana Mozos; Dana Stoian; Alexandru Caraba; Clemens Malainer; Jarosław O Horbańczuk; Atanas G Atanasov Journal: Front Pharmacol Date: 2018-05-23 Impact factor: 5.810
Authors: Vadim V Klimontov; Elena A Koroleva; Rustam S Khapaev; Anton I Korbut; Alexander P Lykov Journal: J Clin Med Date: 2021-12-24 Impact factor: 4.241